(Total Views: 493)
Posted On: 01/06/2022 6:13:29 PM
Post# of 145879
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Re: generactor #114046
As I recall, we held back on submitting the BTD for mTNBC with brain metastasis because we wanted to see how the FDA responded to the first BTD submittal. This may be more of a question for Ohm, but I wonder if sacituzumab can penetrate the brain barrier.
Quote:
meaning leronlimab hasn't shown a substantial improvement over the approved SOC, sacituzumab
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)
My comments are just my opinions and should NOT be taken as investment advice.